Dr. Di Wu | Regenerative Medicine | Best Researcher Award

Dr. Di Wu | Sun Yat-Sen University | China

 

Dr. Di Wu is a developer and innovator in regenerative medicine and organoid technology, serving today as Chief Technology Officer and Principal Investigator at iORGANtech Co., Ltd., leading the Laboratory of Developmental and Regenerative Biology. Drawing on a strong foundation in developmental and pluripotent stem-cell biology, Dr. Di Wu’s expertise merges organoid engineering with translational regenerative research to uncover mechanisms underlying human development and disease, and to advance in vitro modeling platforms with clinical and drug-development potential.

Professional Profile

SCOPUS

Summary of Suitability

Dr. Di Wu is a highly qualified and accomplished researcher in the fields of regenerative medicine, developmental biology, and disease modeling, with a strong research background in human pluripotent stem cell differentiation, 3D organoid technology, and tissue engineering. His sustained academic contributions, high-impact publications, patented innovations, and leadership in advancing organoid-based research position him as an outstanding candidate for the Best Researcher Award.

Education

Dr. Di Wu completed undergraduate studies at Dalian University, followed by a master’s in Biophysics at Dalian Maritime University, where early work explored regenerative and tissue-repair mechanisms across model organisms such as fruit flies, zebrafish, and mice. Graduate training continued at Sun Yat-sen University, focusing on embryonic development of hepatic and biliary systems and the generation of three-dimensional hepatobiliary organoids from human pluripotent stem cells via multilineage co-differentiation approaches.

Experience

Following doctoral research, Dr. Di Wu joined the translational medicine department of a leading pharmaceutical group, broadening investigations to include organoid differentiation and embryonic development across multiple endoderm-derived tissues—lung, liver, bile duct, pancreas, and intestine. In founding iORGANtech Co., Ltd., Dr. Di Wu now directs a research group devoted to human 3D multi-lineage organoid technologies, strategically extending earlier model studies into scalable regenerative and disease modeling systems.

Research Interests

Dr. Di Wu’s work spans two interlocking domains. In developmental biology, model organisms are used to decipher mechanisms of specification, differentiation, and organogenesis, particularly in tissues originating from endoderm and mesoderm. In disease modeling and regenerative medicine, the focus shifts to directing human pluripotent stem cells toward endodermal lineages to generate functional tissues for replacement therapies, and to develop novel in vitro models that faithfully recapitulate human development and disease pathology.

Awards

Dr. Di Wu has been recognized for contributions to organoid engineering, regenerative biology, and translational modeling, including a series of patented technologies covering organoid preparation, disease modeling platforms (e.g., for colon, bile duct, lung fibrosis), and drug-efficacy screening systems. These patents reflect a trajectory of innovation and impact in developing reproducible, immune-included organoid systems and multi-lineage liver and intestinal models.

Publication Top Notes

Generation of hepatobiliary organoids from human induced pluripotent stem cells

Smoke and Spike: Benzo[a]pyrene Enhances SARS-CoV-2 Infection by Boosting NR4A2-Induced ACE2 and TMPRSS2 Expression

Production of functional hepatobiliary organoids from human pluripotent stem cells

Association of hepatitis C infection and risk of kidney cancer

Human hepatic cancer stem cell markers correlated with immune infiltrates reveal prognostic significance of hepatocellular carcinoma

Conclusion

Dr. Di Wu represents a rising leader in organoid science and regenerative medicine, translating deep expertise in developmental biology and pluripotent stem-cell differentiation into tangible, patentable technologies with applications in disease modeling and therapy screening. From fundamental investigations in model organisms through to multi-lineage human organoid platforms, his trajectory from academic training to translational leadership at iORGANtech underscores a commitment to advancing human health through innovation. His body of work—including organoid generation, disease model development, and patented methodologies—positions the Lab of Developmental and Regenerative Biology at the forefront of organoid research and its translation to therapeutic and pharmaceutical domains.